Comorbidities associated with vitiligo: a ten-year retrospective study
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Background: Vitiligo is a common disorder of depigmentation that has been associated with other autoimmune diseases. No recent large-scale data exist on the rates of comorbidities associated with vitiligo from the United States population. Objectives: To identify the prevalence of comorbidities as well as associated laboratory abnormalities in vitiligo patients. Methods: All medical records dating from January 1, 2000 to June 21, 2011 within the Research Patient Data Repository were evaluated retrospectively using a novel artificial intelligence-based computer program. A total of 3,280 patients carrying the diagnosis of vitiligo were identified using ICD-9 code 709.01. We randomly selected 300 patients and validated the diagnosis by manually reviewing their medical records. These results were used to create a model that was then applied to the larger set yielding 2,441 true vitiligo patients. 1,657 (68%) were diagnosed by dermatologists and 784 (32%) by non-dermatologists. We identified the prevalence of other comorbid autoimmune conditions by searching problem lists of vitiligo patients and collected laboratory data from the first available data point in the system for each patient. Results: Women were more frequently represented (57.6%) than men (42.4%). The majority of vitiligo patients were White/Caucasian (56.9%), followed by Hispanic/Latino (19.4%). 565 (23%) had one of the following comorbidities: 287 thyroid-related, 186 psoriasis, 72 rheumatoid arthritis, 59 alopecia areata, 55 inflammatory bowel disease, 53 systemic lupus and 20 type I diabetes mellitus. 41% had elevated anti-nuclear antibody levels. Almost half of the patients tested had elevated thyroid peroxidase antibodies. Over 50% of the patients tested had low or insufficient levels of 25-OH vitamin D. Conclusion: We found a high prevalence of comorbidities among individuals with vitiligo presenting to teaching hospitals in Boston, Mass. Comorbid autoimmune conditions were seen in 23% of vitiligo patients, thyroid disorders and psoriasis being the most common. Screening for these conditions, especially thyroid disorders, should be considered in vitiligo patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Comorbidities in patients with vitiligo in our study were most often higher than those reported in individuals without vitiligo from other studies (Figure 4).4,8,10,[17][18][19][20]”
From Burden of disease and treatment patterns in patients with vitiligo: findings from a national longitudinal retrospective study in the UK (2024) · cites this paper as [8]
In the citing paper
“The presence of systemic and autoimmune comorbidities, as previously reported, 8 reinforces the autoimmune nature of vitiligo.”
From Burden of disease and treatment patterns in patients with vitiligo: findings from a national longitudinal retrospective study in the UK (2024) · cites this paper as [8]
Citations
Cites
Polyglandular Autoimmune Syndromes: Immunogenetics and Long-Term Follow-Up
Dittmar, M., & Kahaly, G. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021845 · Cited by 367
A pilot study assessing the role of 25 hydroxy vitamin D levels in patients with vitiligo vulgaris
Silverberg, J. I., Silverberg, A. I., Malka, E. S., & Silverberg, N. B. (2010) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.11.024 · Cited by 119
Birlea, S. A., Costin, G., & Norris, D. A. (2008) · Current Drug Targets · doi:10.2174/138945008783954970 · Cited by 116
Statins and Prostate Cancer Diagnosis and Grade in a Veterans Population
Farwell, W. R., DʼAvolio, L., Scranton, R. E., Lawler, E. V., & Gaziano, J. M. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr108 · Cited by 114
Akay, B. N., Bozkir, M., Anadolu, Y., & Güllü, S. (2010) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2010.03605.x · Cited by 109
Generalized Vitiligo Associated Autoimmune Diseases in Japanese Patients Their Families
Narita, T., Oiso, N., Fukai, K., Kabashima, K., Kawada, A., & Suzuki, T. (2011) · Allergology International · doi:10.2332/allergolint.11-oa-0303 · Cited by 107
Perfil epidemiológico dos pacientes com vitiligo e sua associação com doenças da tireoide
Nunes, D. H., & Esser, L. M. H. (2011) · Anais Brasileiros de Dermatologia · doi:10.1590/s0365-05962011000200006 · Cited by 96
D'Avolio, L. W., Nguyen, T. M., Farwell, W. R., Chen, Y., Fitzmeyer, F., Harris, O. M., & Fiore, L. D. (2010) · Journal of the American Medical Informatics Association · doi:10.1136/jamia.2009.001412 · Cited by 73
Calcipotriene and Corticosteroid Combination Therapy for Vitiligo
Travis, L., & Silverberg, N. B. (2004) · Pediatric Dermatology · doi:10.1111/j.0736-8046.2004.21418.x · Cited by 70
Psoriasis Regression Analysis of MHC Loci Identifies Shared Genetic Variants with Vitiligo
Zhu, K., Lv, Y.-M., Yin, X., Wang, Z.-X., Sun, L.-D., He, S.-M., Cheng, H., Hu, D.-Y., Zhang, Z., Li, Y., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023089 · Cited by 62
Shankar, D. K., Shashikala, K., & Madala, R. (2012) · Indian Dermatology Online Journal · doi:10.4103/2229-5178.96705 · Cited by 58
Amerio, P., Rollo, D. D., Carbone, A., Auriemma, M., Marra, M. E., Remigis, P. D., Feliciani, C., Tracanna, M., & Tulli, A. (2010) · European Journal of Dermatology · doi:10.1684/ejd.2009.0939 · Cited by 52
Oh, S. H., Kim, T., Jee, H., Do, J. E., & Lee, J. H. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2010.12.007 · Cited by 51
Vitiligo and associated autoimmune disorders: A retrospective hospital-based study in Mumbai, India
Poojary, S. (2011) · Allergologia et Immunopathologia · doi:10.1016/j.aller.2010.12.007 · Cited by 41
1,24-Dihydroxyvitamin D3(tacalcitol) prevents skin T-cell infiltration
Yamanaka, K., Kakeda, M., Kitagawa, H., Tsuda, K., Akeda, T., Kurokawa, I., Gabazza, E. C., Kupper, T. S., & Mizutani, H. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2010.09692.x · Cited by 24
Gamil, H. D., Attwa, E. M., & Ghonemy, S. M. (2010) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.2010.03838.x · Cited by 22
Pradhan, V., Patwardhan, M., Thakkar, V., Kharkar, V. D., Khopkar, U. S., Ghosh, K., Weetman, A. P., Gawkrodger, D. J., & Kemp, E. H. (2011) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2011.04367.x · Cited by 18
Cited by
Lee, H. H., Gwillim, E., Patel, K. R., Hua, T., Rastogi, S., Ibler, E., & Silverberg, J. I. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.08.032 · Cited by 345
The Prevalence of Vitiligo: A Meta-Analysis
Zhang, Y., Cai, Y., Shi, M., Jiang, S., Cui, S., Wu, Y., Gao, X.-H., & Chen, H.-D. (2016) · PLOS ONE · doi:10.1371/journal.pone.0163806 · Cited by 292
Stafford, I. S., Kellermann, M., Mossotto, E., Beattie, R. M., MacArthur, B. D., & Ennis, S. (2020) · npj Digital Medicine · doi:10.1038/s41746-020-0229-3 · Cited by 272
Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial
Rosmarin, D., Pandya, A. G., Lebwohl, M., Grimes, P., Hamzavi, I., Gottlieb, A. B., Butler, K., Kuo, F., Sun, K., Ji, T., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30609-7 · Cited by 271
Current knowledge on psoriasis and autoimmune diseases
McCormick, T., Ayala-Fontanez, N., & Soler, D. (2016) · Psoriasis: Targets and Therapy · doi:10.2147/ptt.s64950 · Cited by 266
Metadata
- Authors
- Sheth, V. M., Guo, Y., & Qureshi, A. A.
- Affiliations
- Brigham and Women's Hospital (US)
- Venue
- Dermatology
- Publisher
- S. Karger AG
- Published
- 2013
- Volume
- 227
- Issue
- 4
- Pages
- 311-315
- ISSN
- 1018-8665 (ISSN-L)
- 1421-9832
- OpenAlex
- W2054293537
- Cited by
- 128
- References
- 17
- Citations by year
- 2026: 8 · 2025: 5 · 2024: 13 · 2023: 19 · 2022: 10 · 2021: 12 · 2020: 11 · 2019: 9 · 2018: 4 · 2017: 12 · 2016: 10 · 2015: 10 · 2014: 5
- FWCI
- 4.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Dermatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › melanin and skin pigmentation
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Dermatology › Hair Growth and Disorders
- Keywords
- vitiligo, comorbidities, autoimmune disease, thyroid dysfunction, psoriasis, rheumatoid arthritis, alopecia areata, inflammatory bowel disease, systemic lupus erythematosus, type 1 diabetes, antinuclear antibodies, thyroid peroxidase antibodies, vitamin D deficiency, prevalence, screening
- MeSH terms
- Alopecia Areata, Antibodies, Antinuclear, Arthritis, Rheumatoid, Boston, Diabetes Mellitus, Type 1, Female, Humans, Iodide Peroxidase, Lupus Erythematosus, Systemic, Male, Middle Aged, Psoriasis, Retrospective Studies, Sex Factors, Thyroid Diseases, Vitamin D, Vitiligo, Inflammatory Bowel Diseases, Comorbidity, Prevalence, Racial Groups
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.